Genomic Valley Biotech open offer at ₹30 in 2026

What was announced on 19 October 2026

Genomic Valley Biotech Limited has announced a mandatory open offer that allows public shareholders to tender up to 7,94,170 equity shares. This offer size represents 26.00% of the company’s voting share capital. The open offer price has been fixed at ₹30 per share. The announcement follows a change in control driven by a large stake acquisition from the existing promoter. For shareholders, the key point is that the offer is positioned as an exit route at a stated cash price.

Why the open offer was triggered

The offer was triggered under Regulation 3(1) and Regulation 4 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The trigger event was the acquisition of a substantial stake by two acquirers from the promoter. As per the disclosed details, the open offer is mandatory because the acquisition results in a level of shareholding that requires an offer to the public shareholders. The open offer is intended to provide an exit opportunity to shareholders who were not part of the negotiated transaction. The terms described in the announcement indicate the offer is not conditional on minimum acceptance.

The share purchase agreement that set the price

The underlying transaction involved a Share Purchase Agreement executed on October 19, 2026. The agreement was between the acquirers and the promoter seller, Mr. Yogesh Agrawal. Under this arrangement, the acquirers purchased 14,07,000 equity shares, representing 46.06% of the voting capital. The total consideration for this promoter stake sale was ₹4.22 crore. A notable feature of the deal is that the negotiated sale price and the open offer price are aligned.

Who the acquirers are and their shareholding before and after

The acquirers are Pankaj Grover and Abhisek Gupta. The disclosure states that they did not hold any stake in the target company before the transaction. After completing the acquisition, their combined holding stands at 46.06%. This post-transaction shareholding is the direct basis for the mandatory open offer to the remaining shareholders. From a process standpoint, the open offer is a standard outcome after such a control or substantial stake acquisition under the takeover regulations.

Open offer terms: size, price, and cash payout

The open offer is for up to 7,94,170 equity shares, or 26% of the voting share capital. The price is ₹30 per share, which matches the negotiated price paid in the promoter transaction. The payment to tendering shareholders will be made in cash. On full acceptance, the aggregate consideration payable to public shareholders is estimated at ₹2.38 crore. The offer is described as unconditional with respect to minimum acceptance levels.

Timeline: Detailed Public Statement due by 27 October 2026

As per the stated schedule, the Detailed Public Statement (DPS) is to be published in newspapers within five working days of the Public Announcement. The disclosed deadline for this is on or before October 27, 2026. Investors typically track the DPS because it consolidates key terms, timelines, and procedural steps. The company has indicated the offer remains subject to regulatory compliance and customary closing conditions. Beyond the DPS date, shareholders generally rely on the official offer schedule for tendering windows and settlement timelines.

Key numbers at a glance

Shareholding pattern context: public majority, no institutions

The shareholding pattern cited in the provided data shows promoters at 46.06% and public shareholding at 53.94%, with FII and DII at 0%. The quarterly and period tables indicate promoter holding has stayed around 46.06% through recent quarters shown, while public holding has been around 53.94%. The absence of institutional holdings (both foreign and domestic institutions at 0%) is also explicitly stated. The number of shareholders is shown in one table as 2,459 (Q2FY26) rising to 2,522 (Q3FY26) and later at 2,448 (Q1FY27), indicating modest movement in the retail base. These figures matter because the open offer is specifically aimed at public shareholders who may choose to tender.

Corporate governance update: AGM extension cited

Separately, the data notes that the Ministry of Corporate Affairs granted a three-month extension for the company’s AGM. The deadline was extended from September 30, 2026 to December 31, 2026 under Section 96(1) of the Companies Act. The reason cited was promoter health concerns. While this AGM extension is not part of the open offer mechanics, it provides context on recent governance-related developments around the company’s compliance calendar.

Market impact: what changes for shareholders now

For shareholders, the practical impact is the availability of a cash exit at a stated price of ₹30 per share for shares tendered in the open offer. The alignment of the open offer price with the promoter’s negotiated sale price is a key disclosure point in the announcement. The offer being unconditional on minimum acceptance reduces uncertainty around whether the offer proceeds based on participation thresholds, as described in the text. At the same time, the outcome for any individual shareholder depends on their decision to tender and the final acceptance process as per the official offer terms. The next concrete milestone highlighted is the DPS publication by October 27, 2026.

Why this event matters

A 46.06% stake purchase combined with a mandatory open offer for 26% is a significant ownership event for a small listed company. It formally changes who holds the controlling promoter-level stake and creates a regulatory pathway for public shareholders to exit at the disclosed price. The open offer also clarifies the cash outlay involved, with ₹4.22 crore paid for the promoter block and up to ₹2.38 crore potentially payable if the open offer is fully accepted. These details help investors understand the structure and scale of the transaction without relying on market speculation.

Conclusion

Genomic Valley Biotech’s mandatory open offer for 26% at ₹30 per share follows the October 19, 2026 share purchase agreement through which Pankaj Grover and Abhisek Gupta acquired 46.06% from promoter Yogesh Agrawal for ₹4.22 crore. The offer provides a cash exit opportunity to public shareholders and is stated to be unconditional regarding minimum acceptance. The next scheduled disclosure is the Detailed Public Statement, due on or before October 27, 2026. Investors tracking the process will likely focus on the DPS and subsequent official tendering timelines released through formal filings and newspaper publications.